相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Richard I. G. Holt et al.
DIABETES CARE (2021)
Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis
Apostolos Tsapas et al.
DIABETES OBESITY & METABOLISM (2021)
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
John B. Buse et al.
DIABETES CARE (2020)
Reducing Type 1 Diabetes Mortality: Role for Adjunctive Therapies?
Jennifer R. Snaith et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2020)
Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes A Systematic Review and Network Meta-analysis
Apostolos Tsapas et al.
ANNALS OF INTERNAL MEDICINE (2020)
Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes: PRONTO-T2D
Thomas Blevins et al.
DIABETES CARE (2020)
Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: Results from the 26-weekPRONTO-T1Dstudy
Leslie Klaff et al.
DIABETES OBESITY & METABOLISM (2020)
International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors
Thomas Danne et al.
DIABETES CARE (2019)
Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
Richard Pratley et al.
LANCET (2019)
Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial
David R. Matthews et al.
LANCET (2019)
Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial
Vanita R. Aroda et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
S. A. Brown et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
A Model-Based Meta-Analysis of 24 Antihyperglycemic Drugs for Type 2 Diabetes: Comparison of Treatment Effects at Therapeutic Doses
Alan Maloney et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
The Cost of Diabetes Care-An Elephant in the Room
Matthew C. Riddle et al.
DIABETES CARE (2018)
Insulin Access and Affordability Working Group: Conclusions and Recommendations
William T. Cefalu et al.
DIABETES CARE (2018)
Cost-related medication non-adherence among US adults with diabetes
Hyojung Kang et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2018)
Effect of metformin on glycaemic control in patients with type 1 diabetes: A meta-analysis of randomized controlled trials
Haiyang Meng et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2018)
Association of Initiation of Basal Insulin Analogs vs Neutral Protamine Hagedorn Insulin With Hypoglycemia-Related Emergency Department Visits or Hospital Admissions and With Glycemic Control in Patients With Type 2 Diabetes
Kasia J. Lipska et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Long-term treatment with metformin in type 2 diabetes and methylmalonic acid: Post hoc analysis of a randomized controlled 4.3 year trial
Mattijs Out et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2018)
Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study
Halis Kaan Akturk et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2018)
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies et al.
DIABETES CARE (2018)
Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials
Julio Rosenstock et al.
DIABETES CARE (2018)
Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial
Martin Tauschmann et al.
LANCET (2018)
Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis
Sonal Singh et al.
DIABETES OBESITY & METABOLISM (2017)
A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients
Mirna S. Abd El Aziz et al.
DIABETES OBESITY & METABOLISM (2017)
Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes The SWITCH 2 Randomized Clinical Trial
Carol Wysham et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes The SWITCH 1 Randomized Clinical Trial
Wendy Lane et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Pancreas transplantation
Patrick G. Dean et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Pancreas transplantation
Patrick G. Dean et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
Vanita R. Aroda et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial
John R. Petrie et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial
Paresh Dandona et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Glucagon-like peptide- I receptor agonists: a systematic review of comparative effectiveness research
Philip A. Levin et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2017)
Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1)
David Russell-Jones et al.
DIABETES CARE (2017)
Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Maria Ida Maiorino et al.
DIABETES CARE (2017)
Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes
Satish K. Garg et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2017)
Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100 U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy
David R. Owens et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2017)
Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes A Systematic Review and Meta-analysis
Nisa M. Maruthur et al.
ANNALS OF INTERNAL MEDICINE (2016)
Mortality in Type 1 Diabetes in the DCCT/EDIC Versus the General Population
John M. Lachin et al.
DIABETES CARE (2016)
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial
Vanita R. Aroda et al.
DIABETES CARE (2016)
Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial
Bo Ahren et al.
DIABETES CARE (2016)
Clinical Considerations for Use of Initial Combination Therapy in Type 2 Diabetes
Avivit Cahn et al.
DIABETES CARE (2016)
Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial
Chantal Mathieu et al.
DIABETES CARE (2016)
New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2)
Y. Terauchi et al.
DIABETES OBESITY & METABOLISM (2016)
EFFECT OF TOTAL DAILY DOSE ON EFFICACY, DOSING, AND SAFETY OF 2 DOSE TITRATION REGIMENS OF HUMAN REGULAR U-500 INSULIN IN SEVERELY INSULIN-RESISTANT PATIENTS WITH TYPE 2 DIABETES
Carol Wysham et al.
ENDOCRINE PRACTICE (2016)
Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes The DUAL V Randomized Clinical Trial
Ildiko Lingvay et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes
Richard M. Bergenstal et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study
Vanita R. Aroda et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
New Insulin Delivery Recommendations
Anders H. Frid et al.
MAYO CLINIC PROCEEDINGS (2016)
Social Determinants of Health, Cost-related Nonadherence, and Cost-reducing Behaviors Among Adults With Diabetes Findings From the National Health Interview Survey
Minal R. Patel et al.
MEDICAL CARE (2016)
Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)
Francesco Giorgino et al.
DIABETES CARE (2015)
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4)
Philip D. Home et al.
DIABETES CARE (2015)
Inhaled Technosphere Insulin Compared With Injected Prandial Insulin in Type 1 Diabetes: A Randomized 24-Week Trial
Bruce W. Bode et al.
DIABETES CARE (2015)
Predictive Low-Glucose Insulin Suspension Reduces Duration of Nocturnal Hypoglycemia in Children Without Increasing Ketosis
Bruce A. Buckingham et al.
DIABETES CARE (2015)
Impact of Fat, Protein, and Glycemic Index on Postprandial Glucose Control in Type 1 Diabetes: Implications for Intensive Diabetes Management in the Continuous Glucose Monitoring Era
Kirstine J. Bell et al.
DIABETES CARE (2015)
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial
M. A. Abdul-Ghani et al.
DIABETES OBESITY & METABOLISM (2015)
One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension
M. C. Riddle et al.
DIABETES OBESITY & METABOLISM (2015)
Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension
H. Yki-Jarvinen et al.
DIABETES OBESITY & METABOLISM (2015)
New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)
G. B. Bolli et al.
DIABETES OBESITY & METABOLISM (2015)
Safety and Efficacy of Insulin Therapy Delivered via a 4mm Pen Needle in Obese Patients With Diabetes
Richard M. Bergenstal et al.
MAYO CLINIC PROCEEDINGS (2015)
Pharmacokinetics and Pharmacodynamics of Insulin Glargine Given in the Evening as Compared With in the Morning in Type 2 Diabetes
Francesca Porcellati et al.
DIABETES CARE (2015)
Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
Jane L. Chiang et al.
DIABETES CARE (2014)
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)
Hannele Yki-Jarvinen et al.
DIABETES CARE (2014)
Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes
Michaela Diamant et al.
DIABETES CARE (2014)
Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis
O. J. Phung et al.
DIABETES OBESITY & METABOLISM (2014)
Glucagon-like peptide-1 receptor agonist and basal insulin combination tre atment for the management of type 2 diabetes: a systematic review and meta-analysis
Conrad Eng et al.
LANCET (2014)
Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis
Andrea C. Tricco et al.
BMJ-BRITISH MEDICAL JOURNAL (2014)
Effect of Patients' Risks and Preferences on Health Gains With Plasma Glucose Level Lowering in Type 2 Diabetes Mellitus
Sandeep Vijan et al.
JAMA INTERNAL MEDICINE (2014)
Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP Study): a randomised, treat-to-target clinical trial
Helena W. Rodbard et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Efficacy of carbohydrate counting in type 1 diabetes: a systematic review and meta-analysis
Kirstine J. Bell et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir Randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas
Melanie Davies et al.
DIABETES CARE (2013)
Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial
H. W. Rodbard et al.
DIABETIC MEDICINE (2013)
Threshold-Based Insulin-Pump Interruption for Reduction of Hypoglycemia
Richard M. Bergenstal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Meta-analysis of insulin aspart versus regular human insulin used in a basal-bolus regimen for the treatment of diabetes mellitus
Simon Heller et al.
JOURNAL OF DIABETES (2013)
Comparative Effectiveness and Safety of Methods of Insulin Delivery and Glucose Monitoring for Diabetes Mellitus A Systematic Review and Meta-analysis
Hsin-Chieh Yeh et al.
ANNALS OF INTERNAL MEDICINE (2012)
Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes A 1-year, randomized, treat-to-target trial (BEGIN Once Long)
Bernard Zinman et al.
DIABETES CARE (2012)
Insulin Therapy and Hypoglycemia
Anthony L. McCall
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2012)
Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial
R. R. Henry et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2012)
Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations
Wendy L. Bennett et al.
ANNALS OF INTERNAL MEDICINE (2011)
Dose-Response Effects of Insulin Glargine in Type 2 Diabetes
Zhihui Wang et al.
DIABETES CARE (2010)
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
Michaela Diamant et al.
LANCET (2010)
Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis
Sumeet R. Singh et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2009)
Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis
E. Mannucci et al.
DIABETES OBESITY & METABOLISM (2009)
Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATETM study
L. Blonde et al.
DIABETES OBESITY & METABOLISM (2009)
SAFE AND SIMPLE EMERGENCY DEPARTMENT DISCHARGE THERAPY FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS AND SEVERE HYPERGLYCEMIA
Ambika Babu et al.
ENDOCRINE PRACTICE (2009)
Long-acting insulin analogues versus NPH human insulin in type 2 diabetes - A meta-analysis
Matteo Monami et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2008)
Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial
P. C. Bartley et al.
DIABETIC MEDICINE (2008)
10-year follow-up of intensive glucose control in type 2 diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the diabetes control and complications Trial/Epidemiology of diabetes interventions and complications (DCCT/EDIC) study
Patricia A. Cleary et al.
DIABETES (2006)
A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes
Kjeld Hermansen et al.
DIABETES CARE (2006)
Insulin glargine or NPH combined with metformin in type 2 diabetes:: the LANMET study
H Yki-Järvinen et al.
DIABETOLOGIA (2006)
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
DM Nathan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial
RE Ratner et al.
DIABETIC MEDICINE (2004)
Outpatient insulin therapy in type 1 and type 2 diabetes mellitus - Scientific review
DE DeWitt et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes - A 1-year randomized controlled trial
PA Hollander et al.
DIABETES CARE (2003)
The treat-to-target trial - Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients
MC Riddle et al.
DIABETES CARE (2003)
A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes
F Whitehouse et al.
DIABETES CARE (2002)
分享论文
